Hybio Pharmaceutical Sincerely Invites Global Partners to Gather at 2025 DCAT Week
In 2025, DCAT Week will be grandly held in New York, USA, from March 17th to 20th (local time). It is Hybio Pharmaceutical’s honor to participate in this event and meet with global pharmaceutical industry partners at the Jacob K. Javits Convention Center in New York. For us, this participation is not only an opportunity for Hybio Pharmaceutical to learn and exchange ideas in the field of high-end complex formulation development and commercialization, but also a chance to explore the global business layout. We look forward to discussing the pharmaceutical R&D and innovation ecosystem with global partners and sincerely welcome your arrival.
DCAT Week is the premier global event held annually in New York City, targeting companies engaged in the biopharmaceutical manufacturing value chain. More than 700 global member enterprises participate in this industry event, including global biopharmaceutical companies and their upstream and downstream industrial chain enterprises.
Driven by R&D Innovation, Building a Highland of Peptide Drug Technology
Founded in 2003, after more than 20 years of development, Hybio Pharmaceutical's R&D Center has been successively recognized by the National Development and Reform Commission and the Ministry of Science and Technology as the "National and Local Joint Engineering Laboratory of Peptide Drugs", "National Public Experimental Center for Peptide Innovative Drugs" and "National Pilot Technology Platform for Peptide Drug Preparation".
Currently, Hybio Pharmaceutical has established internationally leading and domestically first-class laboratories for peptide drug synthesis, purification, lyophilization, quality research, formulation research and pilot-scale amplification. More than 300 sets of special equipment have been imported from the United States, Germany, Switzerland and other countries, including automatic Peptide Synthesis systems, rapid microwave peptide synthesis systems, large-capacity purification systems, electrostatic orbitrap ultra-high-resolution mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and ion trap mass spectrometry.
As an advanced enterprise in the peptide drug industry, the company is equipped with a full-process R&D platform for drug development. Hybio Pharmaceutical's R&D Center consists of 7 departments, with platforms for innovative drug introduction and evaluation, peptide drug synthesis process development, peptide formulation R&D, peptide drug quality research, peptide drug stability and methodology verification, non-clinical and clinical trial management, and international and domestic drug registration. Through the full cooperation of these 7 departments, it provides full-chain support for peptide innovative drugs from discovery to market launch.
Dual Bases for Formulations and APIs to Ensure Global Supply
At present, the company has established Pingshan Branch as a formulation production base, which is responsible for the production of formulation products. The factory is built in accordance with EU and US cGMP standards, covering an area of 25,000 square meters with a construction area of 60,000 square meters. It has introduced internationally advanced production lines, including vial lines and cartridge lines, all equipped with advanced and complete quality systems. The company mainly engages in the production and sales of peptide sterile formulations, and can also provide customers with international high-standard injectable CMO/CDMO services.
The Wuhan API production base has advanced workshop design, large scale and sophisticated equipment. Equipment such as CSbio synthesizers, lysers, Novasep purifiers, and Waters high-performance liquid chromatographs are all imported from international sources. It has complete solid-phase and liquid-phase workshops, and can flexibly choose multiple process routes for different varieties to achieve the optimal balance between cost and quality. The workshop strictly follows cGMP, EU-GMP, and FDA-GMP standards, adopts programmed operations to minimize human errors, and steadily promotes green manufacturing and intelligent production. Currently, the base is continuously expanding its production capacity. Recently, the annual production capacity has jumped from 200 kg to 1 ton, and the second-phase project is also under intensive construction.
Zero-Defect Quality Control Under International Standards
As one of the few domestic enterprises that have integrated the entire industrial chain of peptide drugs "API - formulation - CDMO", Hybio Pharmaceutical is committed to breaking the barriers of complex formulation industrialization through technological innovation. Its cooperation covers many multinational pharmaceutical companies such as Hikma, Ferring, and 3SBio Inc., with products sold to North America, South America, Southeast Asia and other regions around the world.
Hybio Pharmaceutical has always adhered to the development principle of quality first. Its Pingshan formulation production base, Wuhan API production base, and Longhua headquarters R&D center have all passed the on-site inspection of the US FDA. Among them, the Longhua headquarters R&D center and Wuhan API production base have both achieved "zero defects". They have also passed GMP certification inspections by the EU, South Korea, Brazil and other countries for many times, laying a solid foundation for international project declaration and international cooperation.
Through this event, Hybio Pharmaceutical will exchange technical explorations and practical experiences in the field of peptide drugs with global peers. Looking forward to the future, we will continue to be guided by international advanced standards, uphold the development philosophy of innovation-driven and quality-first, and steadily advance the global layout. We look forward to deepening collaborative innovation with domestic and foreign partners and jointly contributing more to the progress of health undertakings.
